Tyra Biosciences (NASDAQ:TYRA) Shares Down 3.3%

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating) shares dropped 3.3% on Thursday . The stock traded as low as $8.83 and last traded at $9.02. Approximately 52,316 shares traded hands during trading, a decline of 41% from the average daily volume of 88,450 shares. The stock had previously closed at $9.33.

Wall Street Analyst Weigh In

Separately, HC Wainwright initiated coverage on shares of Tyra Biosciences in a research report on Thursday, June 23rd. They set a “buy” rating and a $12.00 price target for the company.

Tyra Biosciences Trading Down 3.3 %

The company’s 50-day simple moving average is $8.08 and its two-hundred day simple moving average is $9.66.

Tyra Biosciences (NASDAQ:TYRA – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.16). As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.35 earnings per share for the current fiscal year. Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently modified their holdings of TYRA. Bailard Inc. bought a new position in shares of Tyra Biosciences in the 2nd quarter worth about $92,000. Bank of America Corp DE increased its stake in shares of Tyra Biosciences by 1,020.1% in the 1st quarter. Bank of America Corp DE now owns 64,126 shares of the company’s stock worth $686,000 after acquiring an additional 58,401 shares in the last quarter. Fairmount Funds Management LLC increased its stake in shares of Tyra Biosciences by 99.1% in the 1st quarter. Fairmount Funds Management LLC now owns 1,284,990 shares of the company’s stock worth $13,749,000 after acquiring an additional 639,641 shares in the last quarter. Woodline Partners LP increased its stake in shares of Tyra Biosciences by 0.5% in the 1st quarter. Woodline Partners LP now owns 266,161 shares of the company’s stock worth $2,848,000 after acquiring an additional 1,416 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Tyra Biosciences by 55.5% in the 1st quarter. State Street Corp now owns 203,680 shares of the company’s stock worth $2,179,000 after acquiring an additional 72,670 shares in the last quarter. 99.96% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

(Get Rating)

Tyra Biosciences, Inc, a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

Recommended Stories

Receive News & Ratings for Tyra Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tyra Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.